Novartis Launches Bone Health Campaign for Breast Cancer Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

EAST HANOVER, NJ-If you are a breast cancer patient with bone pain, don’t ignore it; see your doctor. That is the primary message behind an educational campaign Novartis Oncology is launching directly to patients. The campaign encourages women to pay attention to persistent bone pain if they have or have had breast cancer, and to notify their doctor about it. A critical component of the campaign is to help women understand that there are treatment options for metastatic bone pain.

 EAST HANOVER, NJ—If you are a breast cancer patient with bone pain, don’t ignore it; see your doctor. That is the primary message behind an educational campaign Novartis Oncology is launching directly to patients. The campaign encourages women to pay attention to persistent bone pain if they have or have had breast cancer, and to notify their doctor about it. A critical component of the campaign is to help women understand that there are treatment options for metastatic bone pain.

“Learning more about her breast cancer and seeking out new information about treatment options has become crucial for each patient and survivor as these treatment options have expanded,” said Amy Langer, executive director of the National Alliance of Breast Cancer Organizations (NABCO).

The campaign was launched with a series of advertisements placed in consumer publications that reach out specifically to people living with cancer. A major component of the campaign is the Breast Cancer Support Network speakers’ program, in which oncology nurses provide information about bone health during meetings of local breast cancer support groups.

Materials provided by the campaign are available through a toll-free number (1-800-707-0778); a Novartis website on its agent Aredia (pamidronate disodium for injection), used for the treatment of osteolytic bone metastases in patients with multiple myeloma or breast cancer (www.Aredia.net); and display portfolios in oncologists’ offices.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.